Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Investments: 2012-2024

Historic Long-Term Investments for Enanta Pharmaceuticals (ENTA) over the last 10 years, with Jun 2024 value amounting to $42.5 million.

  • Enanta Pharmaceuticals' Long-Term Investments rose 617.59% to $42.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $42.5 million, marking a year-over-year increase of 617.59%. This contributed to the annual value of $29.3 million for FY2022, which is 72.99% down from last year.
  • Latest data reveals that Enanta Pharmaceuticals reported Long-Term Investments of $42.5 million as of Q2 2024, which was up 617.59% from $5.9 million recorded in Q2 2023.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Investments peaked at $115.7 million during Q2 2021, and registered a low of $5.9 million during Q2 2023.
  • Over the past 3 years, Enanta Pharmaceuticals' median Long-Term Investments value was $29.3 million (recorded in 2022), while the average stood at $28.8 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Long-Term Investments crashed by 84.97% in 2023, and later spiked by 617.59% in 2024.
  • Quarterly analysis of 5 years shows Enanta Pharmaceuticals' Long-Term Investments stood at $18.5 million in 2020, then spiked by 380.27% to $88.7 million in 2021, then slumped by 69.62% to $26.9 million in 2022, then tumbled by 84.97% to $5.9 million in 2023, then soared by 617.59% to $42.5 million in 2024.
  • Its Long-Term Investments was $42.5 million in Q2 2024, compared to $5.9 million in Q2 2023 and $15.0 million in Q1 2023.